Vol.43, 2025 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报

2025-02-17

1. Summary of the week

From February 8 to 14, a total of 18 licensing and cooperation deals were signed globally. In the China Biotech Industry, there are 3 in-licensing deals, 1 out-licensing deal, and 1 domestic deal.

Bio-Thera Solutions and Intas Pharmaceuticals signed an out-licensing deal for golimumab biosimilar with a total deal amount of $164.5 million and an upfront payment of $21 million. Roche and Baheal Medical signed a cooperation deal for the approved drug, rituximab. Lexen Pharm and SunNovo signed cooperation deal for the pre-clinical stage assets, LXP2311 and LXP0531.

Globally, 13 deals were announced. The top deal of the week is the cooperation and licensing deal of Xilio Therapeutics and AbbVie for T-cell engagers with a total deal amount of $2,152 million and an upfront payment of $42 million.

2025年2月8日-14日，全球医药市场共签署了18项资产授权和合作协议。中国市场共达成5项交易，包括3项引进交易、1项出海交易和1项国内交易。

唯一的出海交易是百奥泰与Intas Pharmaceuticals就戈利木单抗生物类似药达成美国市场的授权交易，首付款2100万美元，总价值1.645亿美元。值得关注的引进交易是百洋医药获得罗氏制药已上市药物利妥昔单抗在中国大陆地区的独家市场推广权。唯一的国内交易是阳光诺和与立生医药就临床前资产LXP2311和LXP0531达成的合作交易。

国际市场上，本周共签署了13项资产授权和合作协议。最大的一笔交易是Abbvie与Xilio Therapeutics就TCE药物开发达成的合作及选择性许可协议，首付款4200万美元，总价值21.52亿美元。

2. Licensing Deals

2a. China section

2b. Global section

3. M&A Deals

4. Top Deals of 2024

5. 2019-2023 China Innovative Drug Licensing Transactions

About YAFO CAPITAL

Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., EU, and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions. For more information, please visit http://www.yafocapital.com
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。

ACCESS CHINA